|
Dr. Rahul Singhvi was appointed President and CEO of Novavax in August, 2005. He joined the Company in April, 2004 as Vice President, Pharmaceutical Development and Manufacturing Operations and was appointed Senior Vice President and Chief Operating Officer in April, 2005. He is charged with restructuring the company to focus on its core competency of new product development and innovation and drive shareholder value. Prior to joining Novavax, Dr. Singhvi spent 10 years with Merck & Co, most recently serving as Director of Vaccine and Sterile Operations in the Merck Manufacturing Division. In this position Dr. Singhvi was responsible for operating a manufacturing unit producing a new biological product and initiating the start up of a second biological product manufacturing unit. In addition to his functional expertise within process development and manufacturing, Dr. Singhvi was a recognized leader within Merck & Co., Inc. for the depth and breadth of his expertise, and led several cross-functional teams responsible for technology transfer and development of new products.
Dr. Singhvi holds several patents in the area of cell culturing systems and has co-authored numerous publications, book chapters, and abstracts on biochemical engineering and cell physiology.
Education
1987 Bachelor of Technology (IIT, Kanpur, India)
1991 Master of Science degree in Chemical Engineering (MIT)
1994 Doctorate of Science in Chemical Engineering (MIT)
2003 Master of Business Administration (The Wharton School)
| 